​

Savara Stock (NASDAQ:SVRA)

ForecastRevenueOwnershipFinancialsChart
Savara by TradingView

Previous Close

$6.94

52W Range

$1.89 - $7.00

50D Avg

$4.55

200D Avg

$3.25

Market Cap

$1.41B

Avg Vol (3M)

$1.98M

Beta

0.22

Div Yield

-

SVRA Company Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

59

IPO Date

Apr 28, 2017

Website

SVRA Performance

SVRA Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-103.20M$-60.01M$-38.84M
Net Income$-95.88M$-54.70M$-38.95M
EBITDA$-103.07M$-59.13M$-37.90M
Basic EPS$-0.48$-0.33$-0.25
Diluted EPS$-0.48$-0.33$-0.25

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 20Aug 06, 20 | 4:30 PM
Q1 20May 07, 20 | 4:30 PM
Q4 19Mar 12, 20 | 4:30 PM

Peer Comparison

TickerCompany
TNGXTango Therapeutics, Inc.
EYPTEyePoint Pharmaceuticals, Inc.
NBTXNanobiotix S.A.
KURAKura Oncology, Inc.
BCAXBicara Therapeutics Inc. Common Stock
RZLTRezolute, Inc.
GHRSGH Research PLC
TYRATyra Biosciences, Inc.
PROKProKidney Corp.
GERNGeron Corporation